Henry Schein Valuation Multiples

Henry Schein is valued at $9.5B as of October 2026, a 1.1x revenue multiple. In the last 12 months, Henry Schein revenue was $14B and Henry Schein EBITDA was $1.2B.

Henry Schein Overview

About Henry Schein

Henry Schein Inc is a solutions company for healthcare professionals. It offers healthcare equipment, products, and services to office-based dental and medical practitioners, as well as alternative sites of care. The company's reportable segments are: Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology. It generates maximum revenue from the Global Distribution and Value-Added Services segment, which includes distribution to the dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services. This segment also includes value-added services such as financial services, continuing education services, consulting, and other practice services.


Founded

1992

HQ

United States

Employees

25.0K

Financials (LTM)

Revenue: $14B
EBITDA: $1.2B

EV

$15B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Henry Schein Financials

Henry Schein reported last 12-month revenue of $14B and EBITDA of $1.2B.

In the same LTM period, Henry Schein generated $4.3B in gross profit, $1.2B in EBITDA, and $620M in net income.

Revenue (LTM)


Henry Schein P&L

In the most recent fiscal year, Henry Schein reported revenue of $13B and EBITDA of $931M.

Henry Schein is profitable as of last fiscal year, with gross margin of 31%, EBITDA margin of 7%, and net margin of 3%.

See analyst estimates for Henry Schein
LTMLast FY202320242025202620272028
Revenue$14B$13B$12B$13B$13B
Gross Profit$4.3B$4.1B$3.9B$4B$4.1B
Gross Margin31%31%31%32%31%
EBITDA$1.2B$931M$834M$888M$931M
EBITDA Margin9%7%7%7%7%
EBIT Margin7%6%6%6%6%
Net Profit$620M$398M$416M$390M$398M
Net Margin5%3%3%3%3%
Net Debt-$3B---

Financial data powered by Morningstar, Inc.

Henry Schein Stock Performance

Henry Schein has current market cap of $9.5B, and enterprise value of $15B.

Market Cap Evolution


Henry Schein's stock price is $84.95.

Henry Schein share price increased by 1.2% in the last 30 days, and by 30.5% in the last year.

Henry Schein has an EPS (earnings per share) of $3.57.

See more trading valuation data for Henry Schein
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$15B$9.5B0.8%1.2%-3.1%30.5%$3.57

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Henry Schein Valuation Multiples

Henry Schein trades at 1.1x EV/Revenue multiple, and 12.5x EV/EBITDA.

See NTM and 2027E valuation multiples for Henry Schein

EV / Revenue (LTM)


Henry Schein Financial Valuation Multiples

As of October 29, 2026, Henry Schein has market cap of $9.5B and EV of $15B.

Henry Schein has a P/E ratio of 15.3x.

LTMLast FY202320242025202620272028
EV/Revenue1.1x1.1x1.2x1.2x1.1x
EV/EBITDA12.5x15.8x17.6x16.5x15.8x
EV/EBIT14.4x19.4x21.1x20.1x19.4x
EV/Gross Profit3.4x3.6x3.8x3.7x3.6x
P/E15.3x23.8x22.8x24.3x23.8x
EV/FCF28.9x28.2x46.9x22.2x28.2x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Henry Schein Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Henry Schein Margins & Growth Rates

Henry Schein grew revenue by 5% and EBITDA by 27% in the last fiscal year.

In the most recent fiscal year, Henry Schein reported gross margin of 31%, EBITDA margin of 7%, and net margin of 3%.

See estimated margins and future growth rates for Henry Schein

Henry Schein Margins

Last FY202420252026202720282029
Gross Margin31%32%31%32%
EBITDA Margin7%7%7%9%
EBIT Margin6%6%6%7%
Net Margin3%3%3%4%
FCF Margin4%5%4%4%

Henry Schein Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth5%3%4%5%
Gross Profit Growth6%4%2%6%
EBITDA Growth27%6%5%27%
EBIT Growth36%5%4%36%
Net Profit Growth57%(6%)2%57%
FCF Growth(5%)111%(21%)(5%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Henry Schein Operational KPIs

Henry Schein's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.1M for the same period.

Henry Schein's Rule of 40 is 14% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Henry Schein's Rule of X is 21% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Henry Schein
LTMLast FY202320242025202620272028
Rule of 4013%14%---
Bessemer Rule of X19%21%---
Revenue per Employee-$0.5M---
Opex per Employee-$0.1M---
Opex to Revenue-25%26%26%25%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Henry Schein Competitors

Henry Schein competitors include Indutrade, Bidcorp Group, Finning International, Sodexo, Andritz, Addtech, Applied Industrial Technologies, Core & Main, Avnet and QXO.

Most Henry Schein public comparables operate across Wholesale Distribution.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Indutrade$3.2B$548M3.2x2.9x19.1x16.7x
Bidcorp Group$15B$1B0.7x0.7x9.7x9.3x
Finning International$7.5B$868M1.5x1.4x12.7x11.7x
Sodexo$27B$1.2B0.5x0.5x11.6x9.1x
Andritz$8.8B$949M0.9x0.9x8.8x8.3x
Addtech$2.3B$409M4.0x3.7x22.2x20.4x
Applied Industrial Technologies$5B$618M2.2x2.2x17.9x17.5x
Core & Main$7.6B$919M1.3x1.3x11.2x10.8x

This data is available for Pro users. Sign up to see all Henry Schein competitors and their valuation data.

Start Free Trial

Henry Schein VC Funding History

Before going public, Henry Schein raised $250M in total equity funding, across 1 round.


Henry Schein Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Jan-25Strategic investmentKKR$250M-Henry Schein announced a strategic partnership with KKR on January 29, 2025, including a USD250 million investment through newly issued common shares. KKR already held shares and expected the additional investment to bring its position to approximately 12%, making it the largest shareholder other than index funds. The agreement also permitted additional open market purchases up to a 14.9% ownership limit. Max Lin and Dan Daniel were appointed to join the board as independent directors under the partnership arrangements. The companies planned to work together on operational improvements and other opportunities to support Henry Schein’s strategy. The share issuance was completed on May 16, 2025, when Henry Schein issued 3,285,151 shares at approximately USD76.10 each. The USD250 million amount represents the new investment rather than KKR’s total historic shareholding cost. Existing public market purchases and the permission to acquire further shares are not themselves additional financing rounds.

Acquisitions by Henry Schein

Henry Schein has acquired 32 companies to date.

Last acquisition by Henry Schein was on March 3rd 2025. Henry Schein acquired R Weinstein Pharmaceuticals Medical Products for undisclosed valuation.

See M&A valuation multiples

Latest Acquisitions by Henry Schein

R Weinstein Pharmaceuticals Medical Products
Acentus
TriMed
Shield HealthCare
Description
R Weinstein Pharmaceuticals Medical Products is a distributor of pharmaceuticals, vaccines, medical devices, and supplies headquartered in the U.S. Virgin Islands, maintaining inventory for next-day delivery to healthcare providers in the Caribbean, United States, and Canada. The company stocks over 5,000 SKUs including Pfizer vaccines, BD syringes, and McKesson diagnostics, serving 500 clinics and hospitals annually. Consultants provide product training and compliance support for treatments in oncology, cardiology, and infectious diseases.
Acentus is a UK-based supplier of home-delivered medical equipment and consumables for patients with chronic conditions. It provides oxygen therapy devices, mobility aids, wound care products, and enteral feeding systems via next-day delivery nationwide. The company serves NHS trusts and private care providers from distribution centers in Leeds and Bristol, stocking over 5,000 SKUs tailored for respiratory, diabetes, and palliative care needs.
TriMed is a designer of orthopedic implants and fixation systems for upper and lower extremity fractures. Systems target distal radius, wrist, ulna, clavicle, elbow, forearm, fifth metatarsal, and ankle pathologies using minimally invasive techniques and anatomically contoured plates.
Shield HealthCare is a Valencia, California-headquartered supplier of home medical products encompassing wound dressings, ostomy pouches, incontinence supplies, enteral feeding formulas, urological catheters, and breast pumps. The company ships directly to patients via its e-commerce platform serving the United States.
HQ CountryUnited StatesUnited StatesUnited StatesUnited States
HQ City
Honolulu, HI
Dallas, TX
Los Angeles, CA
-
Deal Date3 Mar 202520 Nov 202420 Dec 20233 Aug 2023
Valuationundisclosedundisclosed$550M$411M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Henry Schein acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by Henry Schein

Henry Schein has invested in 1 company to date.

Latest investment by Henry Schein was on April 3rd 2018. Henry Schein invested in Henry Schein One in their Strategic investment round.

See VC round multiples

Latest Investments by Henry Schein

Henry Schein One
Description
-
HQ CountryUnited States
HQ City
-
Deal Date3 Apr 2018
RoundStrategic investment
Raisedundisclosed
InvestorsHenry Schein; Internet Brands
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Henry Schein investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Henry Schein

When was Henry Schein founded?Henry Schein was founded in 1992.
Where is Henry Schein headquartered?Henry Schein is headquartered in United States.
How many employees does Henry Schein have?As of today, Henry Schein has over 25K employees.
Who is the CEO of Henry Schein?Henry Schein's CEO is Frederick M. Lowery.
Is Henry Schein publicly listed?Yes, Henry Schein is a public company listed on Nasdaq.
What is the stock symbol of Henry Schein?Henry Schein trades under HSIC ticker.
When did Henry Schein go public?Henry Schein went public in 1995.
Who are competitors of Henry Schein?Henry Schein main competitors include Indutrade, Bidcorp Group, Finning International, Sodexo, Andritz, Addtech, Applied Industrial Technologies, Core & Main, Avnet, QXO.
What is the current market cap of Henry Schein?Henry Schein's current market cap is $9.5B.
What is the current revenue of Henry Schein?Henry Schein's last 12 months revenue is $14B.
What is the current revenue growth of Henry Schein?Henry Schein revenue growth (NTM/LTM) is 4%.
What is the current EV/Revenue multiple of Henry Schein?Current revenue multiple of Henry Schein is 1.1x.
What is the current EBITDA of Henry Schein?Henry Schein's last 12 months EBITDA is $1.2B.
What is Henry Schein's EBITDA margin?Henry Schein's last 12 months EBITDA margin is 9%.
What is the current EV/EBITDA multiple of Henry Schein?Current EBITDA multiple of Henry Schein is 12.5x.
What is the current FCF of Henry Schein?Henry Schein's last 12 months FCF is $508M.
What is Henry Schein's FCF margin?Henry Schein's last 12 months FCF margin is 4%.
What is the current EV/FCF multiple of Henry Schein?Current FCF multiple of Henry Schein is 28.9x.
How many companies Henry Schein has acquired to date?As of October 2026, Henry Schein has acquired 32 companies.
What was the largest acquisition by Henry Schein?$737M acquisition of Biotech Dental on 16th December 2022 was the largest M&A Henry Schein has done to date.
What companies Henry Schein acquired?Henry Schein acquired Biotech Dental, TriMed, Shield HealthCare, SmartPak Equine, Medivet, Arseus Dental Solutions, Arseus Lab, Arseus, Logiciel Julie, Maravet, and 22 other companies.
In how many companies Henry Schein has invested to date?As of October 2026, Henry Schein has invested in 1 company.
What was the last Henry Schein investment?On 3rd April 2018 Henry Schein invested in Henry Schein One, participating in a Strategic investment round, alongside Internet Brands.
In what companies Henry Schein invested in?Henry Schein invested in Henry Schein One.

See public comps similar to Henry Schein

Lists including Henry Schein

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial